Filing Flows › Alamar Biosciences (ALMR) › Q3 2026
Alamar Biosciences (ALMR) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Alamar Biosciences (ALMR) reported revenue of $33.5M for the third quarter 2026 (Q3 2026), +68% from a year earlier and +14% from the quarter before. Operating margin was -45.1%, net loss $13.3M (39.8% of revenue).
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.5M | +14% | +68% |
| Operating profit | −$15.1M | — | — |
| Net earnings | −$13.3M | — | — |
| Operating cash flow | −$14.7M | — | — |
What changed
Revenue was $33.5M in Q3 2026, up 68% year over year and up 14% from the previous quarter. Consumables was the largest line at 53% of revenue. Consumables added $7.9M year over year (up 79%), 58% of the total change.
Gross margin was 61.5%, up 1.8 points from a year earlier. Operating costs exceeded revenue by $15.1M, an operating margin of -45.1%. Operating expenses grew 81% against revenue growth of 68%. The fastest-growing cost line was SG&A (+105%). The quarter ended with a net loss of $13.3M, wider than the previous quarter's $13.2M loss.
Operating cash flow was −$14.7M. Non-cash charges added back $1.4M of depreciation and amortization and $3.9M of share-based compensation. Working capital and other items used $6.7M. Capital expenditures of $463K exceeded it, leaving free cash flow of −$15.2M.
Questions
What was Alamar Biosciences' revenue in the third quarter 2026?
Alamar Biosciences (ALMR) reported revenue of $33.5M for the third quarter 2026 (Q3 2026), +68% from a year earlier and +14% from the quarter before.
Was Alamar Biosciences profitable in the third quarter 2026?
Operating loss was $15.1M (-45.1% of revenue) and net loss $13.3M.
Source: Alamar Biosciences 10-Q on SEC EDGAR.